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Little is known about long-term outcomes following a second breast cancer diagnosis. We describe the epidemiology, characteristics
and prognosis of second breast cancers in an Italian cohort. We identified women with two breast cancer diagnoses from 24278
histology records at a Tuscan breast cancer service between 1980 and 2005, and determined their survival status. Disease-specific
survival from second diagnosis was examined using Cox regression analyses. Second cancers were identified in 1044 women with a
median age of 60 years. In all 455 were ipsilateral relapses and 589 were contralateral cancers. Median time between first and second
diagnosis was 63.4 months. The majority of second cancers was small invasive or in situ tumours. Estimated 10-year survival from a
second cancer diagnosis was 78%. Survival was poorest when the second cancer was large (HR¼2.26) or node-positive (HR¼3.43),
when the time between the two diagnoses was o5 years (HR¼1.45), or when the diagnosis was in an earlier epoch (HR¼2.20).
Second tumours were more likely to be large or node-positive if the first breast cancer had these features. Prognosis following a
second breast cancer in this cohort was generally good. However, large or node-positive second tumours, and shorter intervals
between diagnoses were indicators of poorer survival.
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Breast cancer (BC) is estimated to be the most prevalent cancer in
the world (Parkin et al, 2005). Earlier diagnosis and better therapy
have improved survival from BC. Information relevant to the care
of this group of such women, who have an elevated risk of a second
BC, is relevant to population health and clinical practice. Few
studies have examined a second BC in well-defined series, and little
is known about the characteristics and long term outcome in
affected women (Grunfeld et al, 2002).
We report on the largest clinically defined cohort (to date) of
second BC events, based on consecutive cases in a major breast
service in Tuscany, and including women with ipsilateral breast
relapse (IBR) and contralateral breast cancer (CBC). We aim to
describe the epidemiology and clinical characteristics of second
BCs, and to identify factors associated with poorer survival
following a second BC diagnosis. The focus of our study is
therefore prognosis following second BC events and not predictors
of its occurrence.
MATERIALS AND METHODS
Eligible participants consisted of all women with a prior primary
BC (invasive or in situ) who were diagnosed with a second
metachronous BC (X6 months after the first cancer) in 1980–2005
at the study centre. We searched the clinical and pathology
archives of the Centro per lo Studio e la Prevenzione Oncologica
(CSPO), identifying women with histology records (surgical or
needle histology) indicating two BC diagnoses separated by at least
6 months. Medical records were then reviewed to verify eligibility.
Centro per lo Studio e la Prevenzione Oncologica is Florence’s
main breast screening and diagnostic service, and is the only
centre in the region that provides follow-up services for women
with BC. Surveillance consists of two-view mammography
complemented by clinical examination (with more frequent
clinical examination in the initial 5 years in women treated with
breast conservation). Centro per lo Studio e la Prevenzione
Oncologica archives have ongoing data linkage to population
cancer and mortality registries in the Tuscan region.
We use the term second BC (‘second cancer’) when describing
all cases, but define two subgroups eligible for inclusion: women
with (1) ipsilateral breast relapse (IBR), who developed a second
cancer in the breast that was previously affected (including those
with breast relapse and concomitant axillary disease); and (2)
women with CBC, who developed a second cancer in the opposite
breast. Women presenting with metastatic cancer at diagnosis of
the second BC, who represent a very small proportion of women,
were not considered for this study as histology verification is
inconsistently available in these cases; inclusion might bias
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difficulty in ascertaining whether the metastases were related to the
first or second cancer event. Women presenting primarily with
nodal metastases or chest wall recurrences (following mastectomy
for the first cancer) were not eligible for inclusion in this study.
Data retrieved from clinical records included date of birth; date
of diagnosis, histology and pathological T and N category of the
first BC; date of diagnosis, side, histology and pathological T and N
category of the second cancer; presence or absence of symptoms at
diagnosis of second cancer; surgical management; and date of last
follow-up. Survival status was assessed directly for patients
regularly followed up at CSPO or according to the regional
Mortality Registry for cases lost to active follow-up. Linkage with
the Mortality Registry for cause of death was complete to 31
December 2005, and ascertainment of outcomes was 97% complete
to 31 December 2006. Data on treatment were not available for this
study, but in our setting, it comprises radiotherapy following
breast conservation and (since about 1988) adjuvant systemic
therapy.
Statistical analysis
Analyses are presented for all second cancers collectively and for
each group (IBR and CBC). Descriptive data are reported on key
variables including histology and tumour stage distribution for
both the first and the second cancers. Time between occurrence of
the first cancer and histological diagnosis of a second cancer
(‘disease-free interval’, DFI), and time from second diagnosis to BC
death, were calculated. When comparing features of the second
tumour with features of the first tumour, data are paired and the
McNemar’s w
2 test was used. When comparing the IBR cases with
the CBC cases, groups are independent and the w
2 test was used.
To determine the prognostic effect of features of the second
cancer, we examined disease-specific survival from the second
cancer diagnosis. Survival from diagnosis of the first cancer will be
the subject of a separate study. For subjects who were alive at the
end of follow-up or had died from a different cause, observations
were censored at date of their last observation (normally 31
December 2006) or date of death. Ten-year survival was estimated
using the Kaplan–Meier method. Multivariate Cox regression
analysis was performed using the following covariates: (a) age at
second cancer diagnosis (o50, 50–69, X70 years); (b) time from
first to second cancer (DFI); (c) stage (pT and pN category) of the
second cancer; (d) time period in which the second cancer was
diagnosed (1980–97, 1998–2005); and (e) type of second cancer
(IBR or CBC). Models were fitted separately for IBR and CBC cases,
as well as for all second cancers. Results are expressed in terms of
hazard ratios (HR) and 95% confidence intervals (CI).
The Cox regression model was used to identify features of the
second tumour that had the most significant adverse influence on
prognosis following its diagnosis. Multivariate logistic regression
analyses were then used to identify which features of the first BC
predicted such second BC. The covariates under consideration
were (a) age at first cancer diagnosis (o50, 50–69, X70 years); (b)
stage of the first cancer (pT and pN category); and (c) histology of
the first cancer (invasive ductal, DCIS, other invasive). Note that
this analysis is designed to predict particular features of a second
tumour and not the occurrence of a second tumour.
All statistical analyses were performed using the STATA
software, release 8.0.
RESULTS
Second BCs were identified in 1044 women from 24278 breast
histology records: IBR in 455 subjects and CBC in 589 (Table 1).
The median age at diagnosis of the second cancer was 60 years
(IQR 51–70). Follow-up was available in all but 36 cases (20 IBR,
16 CBC), which were excluded from outcome analyses but retained
in descriptive analyses. The median follow-up period from the
occurrence of the first cancer was 13.7 (IQR 9.0–18.1) years. There
were 181 BC deaths and 62 from other causes (Table 1). Second
cancers were more likely to be detected asymptomatically (67.0%)
than symptomatically (33.0%, Po0.001). However, the proportion
of symptomatic cases did not differ between IBR and CBC
(P¼0.21, Table 1).
The majority of second cancers was small invasive or in situ
(77% were pTis or pT1). DCI comprised 12%, invasive ductal 56%
and other histological types 32%. Of CBC cases, 56% were node
negative, 20% were node positive, and in 24% node status was
unknown. There was a significant difference between IBR and CBC
with respect to the histological type of the tumour (Po0.0001),
more IBR cases being DCIS, whereas more CBC cases were invasive
lobular. Similarly, there was a significant difference between
the two groups in the histological types of the first tumour
(Po0.0001); more IBR had been diagnosed with DCIS
previously compared with those with CBC (17.1 vs 5.8%).
Significant differences in the distribution of pT categories between
IBR and CBC were also seen for both first and second tumours
(Table 1).
Table 2 summarises data on size (pT) of second tumours
according to the size of the first tumour and the type of second
cancer (IBR or CBC). For women diagnosed with CBC, the second
tumour tended to be smaller than the first. Of those with known
tumour size of both first and second cancers, 80.5% (409/508)
of second cancers were pT1 or smaller, compared with 58.5%
(297/508) of first cancers (Po0.0001). However, this difference was
not observed in women with IBR, whose second tumour was more
likely to be of a similar size to the first tumour (83.3% (334/401) of
second cancers and 81.5% (327/401) of first cancers were pT1 or
smaller, P¼0.5).
Figure 1 shows Kaplan–Meier survival curves for IBR, CBC and
all second cancers. The estimated 10-year survival rate from IBR
was 77.9%, from CBC, 77.3% and overall in second cancers 77.6%.
In univariate analysis significantly poorer survival was observed
with younger (o50 years) and older (469 years) age at second
cancer diagnosis (P¼0.03), a short interval from first to second
cancer (P¼0.001), larger tumour size (Po0.0001), positive nodes
(Po0.0001), and cancers diagnosed during the earlier time period
(Po0.0001). These effects were similar for IBR and CBC cases and
so both groups were included in the final multivariate model. The
multivariate Cox regression model is presented in Table 3 showing
the proportional hazard ratios (HR) and 95% CI for second BC
variables. The strongest predictor variables for survival in this
model were pT and pN categories, although time between first and
second cancer, and epoch of diagnosis of second cancer, also
remained significant. There was no evidence of a difference in
survival between IBR and CBC.
The Cox model indicates that second cancers that were 2cm or
larger or node positive had a poor prognosis. Table 4 summarises
multivariate analysis of the features of the first cancer that
predicted these features in the second tumour: women whose first
cancer was large or node positive at diagnosis were more likely to
have large or node-positive second cancer.
DISCUSSION
The characteristics of second BCs in women presenting to a major
centre in Tuscany represents the largest series to date to include
both IBR and CBC, with data on outcomes in almost all subjects.
As BC survival is improving, clinicians will be providing care to
increasing number of women at risk of developing a second cancer
in either breast. Women who experienced IBR or CBC in this study
were on average around 60 years of age when they experienced the
second BC event. This is not an old population in the context of life
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to be diagnosed in asymptomatic women, and are generally smaller
tumours than the initial cancer in the same women.
Overall 10-year survival from diagnosis of the second cancer was
77.6%, and the median time between first and second cancer
diagnosis was 63.4 months. A shorter time from first till second
cancer diagnosis was associated with poorer survival. Ten-year
survival estimates in our study are similar to survival estimates of
75% observed for first invasive cancers in the Swedish two-county
study (Tabar et al, 1992), and the 73% observed in first invasive
cancers diagnosed in the 1990s in the West Midlands, UK
(G Lawrence, personal communication).
Many studies have looked at IBR and reported on factors
predicting local recurrence. We have taken a different approach by
focusing on the identification of features associated with prognosis
once a second BC has occurred (rather than predictors of
recurrence) and have included CBC as well as IBR. Most studies
of CBC have included small number of cases and limited follow-up
(Grunfeld et al, 2002). The exception to this is a study that
reported on stage-related survival in CBCs only and showed good
prognosis in early-stage tumours (Schootman et al, 2006). We
recognise that IBR and CBC are essentially different events and for
this reason we have reported data separately in the two groups.
Our summary of key features (Table 1) highlights both similarities
and differences in second cancers. Variables associated with
prognosis in survival analysis were similar for both IBR and CBC.
We were unable to report on tumour grade and hormone receptor
status because of incomplete or non-availability of such data. It
should be noted that Rack and colleagues, in a study of
locoregional breast relapse found that tumour grade was not
independently associated with risk of death following relapse
(Rack et al, 2003).
The distribution of times between first and second cancer
diagnosis in this cohort (both IBR and CBC) provides evidence
supporting long-term follow-up of women after BC. Currently,
some groups recommend only limited follow-up (National
Institute for Clinical Excellence, 2002; The Association of Breast
Surgery @ BASO, 2005). However, our study suggests that a
Table 1 Second breast cancers in Tuscan women: key characteristics and outcomes
Variable Category/quantity
IBR
(N¼455)
CBC
(N¼589)
All second
cancers
(N¼1044) P-value
a
Follow-up time from first cancer
b Median (IQR), years 13.3 (9.0–17.1) 14.5 (9.1–18.7) 13.7 (9.0–18.1) NA
Time from second cancer to breast
cancer death
Median (IQR), years 3.1 (1.9–5.3) 3.8 (1.9–6.2) 3.3 (1.9–5.7) NA
Breast cancer deaths 78 103 181 NA
Deaths from other causes 14 48 62 NA
Features of second cancer
Time from first to second cancer (DFI) Median (IQR), months 57.4 (30.5–107.6) 68.0 (36.0–122.1) 63.4 (33.2–117.0) 0.029
Age at second cancer Median (IQR), years 59 (50–69) 61 (53–71) 60 (51–70) 0.082
Presentation of second cancer Asymptomatic (%) 314 (69) 385 (65) 699 (67) 0.214
Symptomatic (%) 141 (31) 204 (35) 345 (33)
pT category of second cancer pTis (%) 70 (15) 55 (9) 125 (12) 0.015
pT1a–c (%) 283 (62) 397 (67) 680 (65)
pT2+ (%) 71 (16) 105 (18) 176 (17)
pTx (%) 31 (7) 32 (5) 63 (6)
Node status of second cancer Negative (%) NA 330 (56) NA NA
Positive (%) NA 116 (20) NA
Not examined (%) NA 143 (24) NA
Histology of second cancer DCIS (%) 72 (16) 55 (9) 127 (12) o0.0001
Invasive ductal (%) 238 (52) 346 (59) 584 (56)
Invasive lobular (%) 55 (12) 115 (20) 170 (16)
Other special types (invasive)
c (%) 22 (5) 43 (7) 65 (6)
Other breast cancers (%) 68 (15) 30 (5) 98 (9)
Surgery for second cancer Mastectomy (%) 248 (55) 233 (40) 481 (46) NA
WLE (%) 183 (40) 342 (58) 525 (50)
Data missing (%) 24 (5) 14 (2) 38 (4)
Features of first cancer
Age at first cancer Median (IQR), years 51 (43–63) 53 (45–62) 53 (44–62) 0.035
pT category of first cancer pTis (%) 85 (19) 37 (6) 122 (12) o0.0001
pT1a–c (%) 257 (56) 271 (46) 528 (51)
pT2+ (%) 85 (19) 227 (39) 312 (30)
pTx (%) 28 (6) 54 (9) 82 (8)
Node status of first cancer Negative (%) 283 (62) 394 (67) 677 (65) o0.0001
Positive (%) 74 (16) 156 (26) 230 (22)
Not examined (%) 98 (22) 39 (7) 137 (13)
Histology of first cancer DCIS (%) 78 (17) 34 (6) 112 (11) o0.0001
Invasive ductal (%) 273 (60) 402 (68) 675 (65)
Invasive lobular (%) 58 (13) 98 (17) 156 (15)
Other special types (invasive)
c (%) 28 (6) 36 (6) 64 (6)
Other breast cancers (%) 18 (4) 19 (3) 37 (4)
DCIS¼ductal carcinoma in situ;I Q R¼interquartile range; NA¼not applicable.
aComparison of IBR with CBC where applicable.
bBased on 1016 subjects (from 1044 subjects)
who had at least one episode of follow-up (from second cancer diagnosis) and verified outcomes through linkage with regional cancer or mortality registry.
cIncludes cases where
histological type of breast malignancy was not specified and those with missing data on type of cancer histology.
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appropriate (Smith et al, 1999; Khatcheressian et al, 2006).
A recent study from Edinburgh, based on 108 relapses (including
35 cases of CBC) makes a similar point, and reports that treatable
breast relapse occurred at a constant rate for at least 10 years
(Montgomery et al, 2007). The benefits of extending surveillance
must be weighed against potential disadvantages in terms of
overdiagnosis and overtreatment although these effects are likely
to be small for this cohort.
Surgical management of CBC was more often breast conserva-
tion than mastectomy, in keeping with the preponderance of small
cancers in this group. In addition, most women with CBC had
node-negative disease, although data on nodal status were not
known in about a quarter of cases (nodes either not excised or data
not notified to the study centre). Although local excision of
in-breast relapse is associated with lower local control than
salvage mastectomy (van der Sangen et al, 2006), a 40% breast
conservation rate in women with IBR in our study might reflect
feasibility of local excision as 62% were small tumours.
Our data do not represent complete population data; however,
the study centre is the region’s main breast diagnostic service with
linkage to population registries, and is the only service in the
Tuscan region which provides organised surveillance for women
with a past BC history. We therefore consider that the majority of
women in our case definition will have been identified and
included. It is also relevant that our study concerned subjects with
two BCs and does not allow calculation of predictors of the
occurrence of a second cancer event nor rates of IBR and CBC.
These were not within the scope of this evaluation; such data on
these issues have been previously reported (Kurtz et al, 1988; Rack
et al, 2003; Montgomery et al, 2007).
One of the clear findings of this study is that the majority of
second BCs was detected in asymptomatic women. These data
suggest that ‘early detection’ of the second cancer may be
occurring during routine follow-up of women with BC. A recent
case–control study found mammography surveillance was asso-
ciated with improved survival in older BC survivors (Lash et al,
2007). As we are considering survival from diagnosis of the second
cancer, estimation of the effect of early detection (based on
symptom status) is likely to be subject to lead-time and length
biases. For this reason we have not included this variable in
survival analysis for purposes of this study. However, we are
currently collecting additional data on symptoms and mode of
diagnosis of second cancers in our cohort to validly quantify the
extent and potential impact of early detection in women with
second cancer events.
The high proportion of asymptomatic second cancers is
consistent with finding that overall second cancers were smaller
than first cancers, although clearly evident for only CBC. As CBC is
essentially a new cancer event, screening may play a larger role in
its diagnosis. Ipsilateral breast relapses are predominantly
recurrences of the initial tumour and so the observed differences
in tumour size may reflect the differing biological nature of these
two cancer events.
Histological types of tumours, for both the first and second
cancer, also differed in distribution between IBR and CBC. This
needs to be interpreted in the context of the long timeframe of the
study (with possible variability in pathology reporting criteria and
pathologists) and that some types were not specified. The
interesting aspect of differences in the distribution of tumour
histology is that it was largely determined (in second cancers) by a
significantly higher proportion of DCIS in IBR than CBC, and a
significantly higher proportion of invasive lobular cancer in CBC
than IBR. Differences in distribution of histology of the first cancer
were similarly influenced by a significantly higher proportion of
DCIS in IBR than CBC.
Poorer disease-specific survival was associated with shorter
times from the first to second cancer event, diagnosis of the second
cancer in an earlier time period, second cancer tumour size
X2cm, and positive nodes. The association between poorer
prognosis and short time from the initial cancer to in-breast
relapse is well known, but such an association has not previously
been clearly demonstrated for CBC (Ciatto et al, 2004). The
association between earlier epoch of diagnosis and poorer survival
has been reported by others in analyses of population data in both
primary early and metastatic BC (Chen et al, 2007; Ernst et al,
2007; Dabakuyo et al, 2008), so we presume this is mainly
indicative of therapy effect. It is also possible that some of this
effect relates to early detection.
Although all the prognostic variables we have described
are relevant to clinicians providing care to women with a
second BC, based on the strongest predictor variables for
survival in our model, pT and pN categories are likely to be more
clinically relevant in prognostication, although the occurrence
Table 2 Pathological tumour size (pT) category of the second breast cancer according to size of the first cancer in Tuscan women
Ipsilateral breast relapse
(% from 455)
Contralateral breast cancer
(% from 589)
Subjects with second cancer
(% from 1044)
First cancer pTis pT1a-c pT2+ pTx pTis pT1a-c pT2+ pTx pTis pT1a-c pT2+ pTx Total (%)
pTis 32 44 7 2 6 21 10 0 38 65 17 2 122 (12)
pT1a–c 33 168 43 13 27 199 34 11 60 367 77 24 528 (51)
pT2+ 5 52 17 11 15 141 55 16 20 193 72 27 312 (30)
pTx 0 19 4 5 7 36 6 5 7 55 10 10 82 (8)
Total (%) 70 (15) 283 (62) 71 (16) 31 (7) 55 (9) 397 (67) 105 (18) 32 (5) 125 (12) 680 (65) 176 (17) 63 (6) 1044 (100)
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Figure 1 Kaplan–Meier disease-specific survival curves for ipsilateral
breast relapse (IBR), contralateral breast cancer (CBC) and all second
cancers.
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of a more aggressive tumour and poorer outcome. The most
powerful predictive features of the first BC, in terms of predic-
ting second cancers with poor prognostic features (second
cancer tumour size X2cm or positive nodes) were larger
tumour size and positive nodes. A larger first BC (X2cm) was a
significant predictor of node metastases on diagnosis of the second
cancer.
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Table 3 Disease-specific survival analysis following diagnosis of a second breast cancer: multivariate Cox proportional hazards model
Variable Hazard ratio 95% confidence interval P-value Number of cases LR test statistic Global P-value
Age at second cancer (years)
o50 1.00 213
50–69 0.80 0.56–1.14 0.220 528 3.99 0.136
469 1.15 0.77–1.71 0.505 267
Time from first to second cancer
X5 years 1.00 529 5.11 0.024
o5 years 1.45 1.05–2.00 0.026 479
Time period of second cancer
1998–2005 1.00 549 19.36 o0.0001
1980–1997 2.20 1.53–3.16 o0.0001 459
pT second cancer
T1 1.00 661
Tis 0.29 0.14–0.64 0.002 121 39.53 o0.0001
T2–4 2.26 1.57–3.25 o0.0001 168
Tx 1.73 1.06–2.83 0.028 58
pN second cancer
pN0 1.00 376
pN+ 3.43 2.20–5.36 o0.0001 134 38.70 o0.0001
pNx (unknown) 3.35 2.00–5.62 o0.0001 138
pNr (previously resected) 1.65 0.85–3.20 0.143 360
Second cancer
CBC 1.00 573 0.63 0.427
IBR 1.29 0.70–2.40 0.413 435
Table 4 Multivariate logistic regression for assessing features of the first breast cancer associated with large or node-positive second breast cancers
Predictive of second cancer with tumour size X 2cm Predictive of second cancer with positive nodes
First cancer variable
Odds ratio
(95% CI) P-value
LR test
statistic
Global
P-value
Odds ratio
(95% CI) P-value
LR test
statistic
Global
P-value
Age at first cancer (years)
o50 1.00 1.00
50–69 0.96 (0.67–1.38) 0.837 1.85 0.396 0.76 (0.52–1.12) 0.171 3.71 0.157
469 1.37 (0.82–2.28) 0.234 0.57 (0.29–1.11) 0.097
pT of first cancer
T1 1.00 1.00
Tis 1.67 (0.44–6.38) 0.452 7.46 0.059 2.18 (0.57–8.35) 0.254 17.36 0.0006
T2–4 1.54 (1.06–2.23) 0.023 2.44 (1.59–3.75) o0.0001
Tx 0.75 (0.37–1.55) 0.439 1.40 (0.68–2.90) 0.360
pN of first cancer
pN0 1.00 1.00
pN+ 1.51 (1.02–2.22) 0.039 4.64 0.098 1.68 (1.10–2.59) 0.017 6.92 0.031
pNx 1.38 (0.73–2.64) 0.324 1.73 (0.86–3.46) 0.122
Histology of first cancer
Invasive ductal 1.00 1.00
DCIS 0.44 (0.11–1.73) 0.241 2.27 0.518 0.63 (0.16–2.44) 0.506 4.35 0.227
Invasive, special types 0.72 (0.31–1.63) 0.427 2.10 (1.02–4.32) 0.043
Invasive (other)
a 1.11 (0.73–1.68) 0.620 1.08 (0.68–1.73) 0.737
aCases where histological type of invasive breast malignancy was not specified and those with missing data on type of cancer histology.
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